Table 2.
Univariate outcomes of GVHD, TRM, EFS and OS after Allogeneic HSCT
| Outcomes | N Eval | Probability (95% CI) |
|---|---|---|
| Maximum overall acute GVHD grade, N (%) | 177 | |
| 0 | 92 (52) | |
| I | 32 (18) | |
| II | 27 (15) | |
| III | 23 (13) | |
| IV | 3 (2) | |
| Acute GVHD (grade I – IV) @ 100 days | 177 | 42 (35 – 49) |
| Chronic GVHD | 176 | |
| @ 1 yr | 45 (37 – 52) | |
| @ 5 yrs | 59 (49 – 69) | |
| Extensive cGVHD | 59 (70%) | |
| Any GVHD @ 5 yrs | 177 | 72 (65 – 79) |
| 100-day mortality | 177 | 8 (5 – 13) |
| Treatment-related mortality | 177 | |
| @ 1 yr | 15 (10 – 20) | |
| @ 5 yrs | 25 (17 – 34) | |
| Relapse/progression | 177 | |
| @ 1 yr | 22 (16 – 28) | |
| @ 5 yrs | 52 (41 – 63) | |
| Event-free survival | 177 | |
| @ 1 yr | 64 (57 – 71) | |
| @ 5 yrs | 22 (13 – 34) | |
| Overall survival | 177 | |
| @ 1 yr | 75 (69 – 82) | |
| @ 5 yrs | 38 (26 – 50) |